These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29399596)

  • 1. Cost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics.
    Adelman MW; McFarland DA; Tsegaye M; Aseffa A; Kempker RR; Blumberg HM
    Open Forum Infect Dis; 2018 Jan; 5(1):ofx269. PubMed ID: 29399596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensified tuberculosis case finding among HIV-infected persons using a WHO symptom screen and Xpert(®) MTB/RIF.
    Adelman MW; Tsegaye M; Kempker RR; Alebachew T; Haile K; Tesfaye A; Aseffa A; Blumberg HM
    Int J Tuberc Lung Dis; 2015 Oct; 19(10):1197-203. PubMed ID: 26459533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture.
    Balcha TT; Sturegård E; Winqvist N; Skogmar S; Reepalu A; Jemal ZH; Tibesso G; Schön T; Björkman P
    PLoS One; 2014; 9(1):e85478. PubMed ID: 24465572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of HIV-positive patients with non-tuberculous mycobacteria positive culture who received anti-tuberculous treatment in Botswana: Implications of using diagnostic algorithms without non-tuberculous mycobacteria.
    Agizew T; Boyd R; Mathebula U; Mathoma A; Basotli J; Serumola C; Pals S; Finlay A; Lekone P; Rankgoane-Pono G; Tlhakanelo T; Chihota V; Auld AF
    PLoS One; 2020; 15(6):e0234646. PubMed ID: 32530972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis.
    Yakhelef N; Audibert M; Ferlazzo G; Sitienei J; Wanjala S; Varaine F; Bonnet M; Huerga H
    PLoS One; 2020; 15(1):e0227138. PubMed ID: 31999746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study.
    Kendall EA; Schumacher SG; Denkinger CM; Dowdy DW
    PLoS Med; 2017 Dec; 14(12):e1002472. PubMed ID: 29240766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
    Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
    BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru.
    Shah L; Rojas M; Mori O; Zamudio C; Kaufman JS; Otero L; Gotuzzo E; Seas C; Brewer TF
    Epidemiol Infect; 2017 Apr; 145(6):1107-1117. PubMed ID: 28162099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-benefit algorithm for rapid diagnosis of tuberculosis and rifampicin resistance detection during mass screening campaigns.
    Donkeng-Donfack VF; Tchatchueng-Mbougua JB; Abanda NN; Ongboulal SM; Djieugoue YJ; Kamdem Simo Y; Mekemnang Tchoupa M; Bekang Angui F; Kuate Kuate A; Mbassa V; Mvondo Abeng Belinga E; Eyangoh S
    BMC Infect Dis; 2022 Mar; 22(1):219. PubMed ID: 35246071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial.
    Agizew T; Chihota V; Nyirenda S; Tedla Z; Auld AF; Mathebula U; Mathoma A; Boyd R; Date A; Pals SL; Lekone P; Finlay A
    BMC Infect Dis; 2019 Dec; 19(1):1058. PubMed ID: 31842773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy.
    Abimbola TO; Marston BJ; Date AA; Blandford JM; Sangrujee N; Wiktor SZ
    J Acquir Immune Defic Syndr; 2012 May; 60(1):e1-7. PubMed ID: 22240465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.
    Dowdy DW; Steingart KR; Pai M
    PLoS Med; 2011 Aug; 8(8):e1001074. PubMed ID: 21857810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis screening costs and cost-effectiveness in high-risk groups: a systematic review.
    Alsdurf H; Empringham B; Miller C; Zwerling A
    BMC Infect Dis; 2021 Sep; 21(1):935. PubMed ID: 34496804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of TB diagnostic technologies in Ethiopia: a modelling study.
    Assebe LF; Erena AK; Fikadu L; Alemu B; Baruda YS; Jiao B
    Cost Eff Resour Alloc; 2024 May; 22(1):43. PubMed ID: 38773636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.